These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31611356)

  • 1. Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126.
    Fischer K; Nguyen K; LiWang PJ
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.
    Xue J; Hoorelbeke B; Kagiampakis I; Demeler B; Balzarini J; Liwang PJ
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3976-89. PubMed ID: 23752505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.
    Xue J; Gao Y; Hoorelbeke B; Kagiampakis I; Zhao B; Demeler B; Balzarini J; Liwang PJ
    Mol Pharm; 2012 Sep; 9(9):2613-25. PubMed ID: 22827601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin.
    Huang X; Jin W; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2011 Oct; 92(Pt 10):2367-2373. PubMed ID: 21715597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.
    Hoorelbeke B; Xue J; LiWang PJ; Balzarini J
    PLoS One; 2013; 8(5):e64132. PubMed ID: 23741304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.
    Alexandre KB; Gray ES; Pantophlet R; Moore PL; McMahon JB; Chakauya E; O'Keefe BR; Chikwamba R; Morris L
    J Virol; 2011 Sep; 85(17):9039-50. PubMed ID: 21697467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
    Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
    J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
    Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.
    Férir G; Huskens D; Palmer KE; Boudreaux DM; Swanson MD; Markovitz DM; Balzarini J; Schols D
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1513-23. PubMed ID: 22607556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.
    Coss KP; Vasiljevic S; Pritchard LK; Krumm SA; Glaze M; Madzorera S; Moore PL; Crispin M; Doores KJ
    J Virol; 2016 Dec; 90(24):11132-11144. PubMed ID: 27707925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.
    Zhou T; Zheng A; Baxa U; Chuang GY; Georgiev IS; Kong R; O'Dell S; Shahzad-Ul-Hussan S; Shen CH; Tsybovsky Y; Bailer RT; Gift SK; Louder MK; McKee K; Rawi R; Stevenson CH; Stewart-Jones GBE; Taft JD; Waltari E; Yang Y; Zhang B; Shivatare SS; Shivatare VS; Lee CD; Wu CY; ; Mullikin JC; Bewley CA; Burton DR; Polonis VR; Shapiro L; Wong CH; Mascola JR; Kwong PD; Wu X
    Immunity; 2018 Mar; 48(3):500-513.e6. PubMed ID: 29548671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.
    Alexandre KB; Moore PL; Nonyane M; Gray ES; Ranchobe N; Chakauya E; McMahon JB; O'Keefe BR; Chikwamba R; Morris L
    Virology; 2013 Nov; 446(1-2):66-76. PubMed ID: 24074568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.
    Sok D; Doores KJ; Briney B; Le KM; Saye-Francisco KL; Ramos A; Kulp DW; Julien JP; Menis S; Wickramasinghe L; Seaman MS; Schief WR; Wilson IA; Poignard P; Burton DR
    Sci Transl Med; 2014 May; 6(236):236ra63. PubMed ID: 24828077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies.
    Daniel Lišková V; Kosztyu P; Kuchař M; Černý J; Bharadwaj S; Petroková H; Vroblová E; Křupka M; Malý M; Zosinčuková T; Šulc J; Rašková Kafková L; Raška M; Malý P
    Front Immunol; 2022; 13():1066361. PubMed ID: 36569830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
    J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
    Yang Q; Li C; Wei Y; Huang W; Wang LX
    Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.
    Mori T; O'Keefe BR; Sowder RC; Bringans S; Gardella R; Berg S; Cochran P; Turpin JA; Buckheit RW; McMahon JB; Boyd MR
    J Biol Chem; 2005 Mar; 280(10):9345-53. PubMed ID: 15613479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells.
    Alexandre KB; Gray ES; Mufhandu H; McMahon JB; Chakauya E; O'Keefe BR; Chikwamba R; Morris L
    Virology; 2012 Feb; 423(2):175-86. PubMed ID: 22209231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.